AI Engines For more Details: Perplexity Kagi Labs You
Cardiac Effects: Isoproterenol stimulates beta-adrenergic receptors in the heart, leading to increased heart rate (positive chronotropic effect), increased myocardial contractility (positive inotropic effect), and vasodilation in peripheral blood vessels. These effects result in increased cardiac output and improved myocardial perfusion. Isoproterenol is used in the management of certain cardiac conditions, such as bradycardia, heart block, and cardiac arrest.
Bronchodilator Effects: Isoproterenol also stimulates beta-adrenergic receptors in the smooth muscle of the bronchi and bronchioles, resulting in bronchodilation. This effect helps relieve bronchoconstriction and improve airflow in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
Treatment of Bradycardia and Heart Block: Isoproterenol may be administered intravenously to increase heart rate and improve cardiac conduction in individuals with symptomatic bradycardia or heart block. It is particularly useful when other interventions such as atropine or pacing are ineffective or unavailable.
Management of Cardiac Arrest: Isoproterenol may be used as a vasopressor agent in the management of cardiac arrest, particularly in cases of profound bradycardia or electromechanical dissociation (pulseless electrical activity). It helps increase myocardial contractility and systemic vascular resistance, thereby improving perfusion pressure and coronary artery blood flow.
Bronchodilator Therapy: Isoproterenol may be administered via inhalation or nebulization for the acute relief of bronchospasm in conditions such as asthma or acute exacerbations of COPD. It provides rapid bronchodilation and symptom relief by relaxing the smooth muscles of the airways.
Dosage and Administration: (-)-Isoproterenol hydrochloride is typically administered intravenously for cardiac indications and via inhalation for bronchodilator therapy. The dosage and administration route may vary depending on the patient's condition, age, weight, and response to treatment. Intravenous administration requires careful titration and continuous cardiac monitoring due to the potential for adverse effects on heart rate and blood pressure.
Side Effects and Adverse Reactions: Common side effects of isoproterenol may include tachycardia, palpitations, headache, tremor, anxiety, flushing, and nausea. Excessive beta-adrenergic stimulation can lead to arrhythmias, myocardial ischemia, and exacerbation of angina pectoris. Bronchospasm may occur as a paradoxical reaction in some individuals, particularly at high doses.
Contraindications: Isoproterenol is contraindicated in individuals with hypersensitivity to sympathomimetic agents, severe hypertension, ventricular arrhythmias, and hypertrophic obstructive cardiomyopathy. It should be used with caution in patients with underlying cardiovascular diseases, hyperthyroidism, diabetes mellitus, and pheochromocytoma.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| Acne | 0.3 | 0.3 | |
| ADHD | 0.8 | 0.8 | |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 0.6 | 0.4 | 0.5 |
| Allergies | 0.3 | -0.3 | |
| Allergy to milk products | 0.3 | 0.3 | 0 |
| Alzheimer's disease | 0.3 | 1.4 | -3.67 |
| Ankylosing spondylitis | 0.6 | 0.3 | 1 |
| Anorexia Nervosa | 0.3 | 1.1 | -2.67 |
| Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
| Asthma | 1.1 | 1.1 | 0 |
| Atherosclerosis | 0.3 | 0.8 | -1.67 |
| Atrial fibrillation | 0.6 | 0.3 | 1 |
| Autism | 1.1 | 1.1 | 0 |
| Autoimmune Disease | 0.3 | 0.5 | -0.67 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.4 | 0.4 | |
| Bipolar Disorder | 0.3 | 0.5 | -0.67 |
| Brain Trauma | 0.3 | 0.8 | -1.67 |
| Cancer (General) | 0.4 | -0.4 | |
| Carcinoma | 0.6 | 0.3 | 1 |
| Celiac Disease | 0.9 | 0.3 | 2 |
| Cerebral Palsy | 0.6 | 0.8 | -0.33 |
| Chronic Fatigue Syndrome | 0.6 | 0.6 | 0 |
| Chronic Kidney Disease | 0.3 | 0.5 | -0.67 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.8 | -1 |
| Chronic Urticaria (Hives) | 0.3 | 0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.8 | -1.67 |
| Cognitive Function | 1.1 | 0.8 | 0.38 |
| Colorectal Cancer | 1.2 | 0.8 | 0.5 |
| Constipation | 0.3 | 0.5 | -0.67 |
| Coronary artery disease | 0.3 | 0.8 | -1.67 |
| COVID-19 | 0.6 | 1.5 | -1.5 |
| Crohn's Disease | 1.1 | 0.8 | 0.38 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 0.5 | 1.1 | -1.2 |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 1.7 | 1.8 | -0.06 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.3 | 0.3 | 0 |
| Endometriosis | 0.6 | 0.5 | 0.2 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 0.6 | 0.3 | 1 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.5 | 0.3 | 0.67 |
| Functional constipation / chronic idiopathic constipation | 0.9 | 0.8 | 0.13 |
| gallstone disease (gsd) | 0.5 | -0.5 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | -0.3 | |
| Generalized anxiety disorder | 0.6 | 1.1 | -0.83 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.7 | 0.7 | |
| Graves' disease | 0.3 | 1.1 | -2.67 |
| Gulf War Syndrome | 0.3 | 0.1 | 2 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 0.8 | 0.3 | 1.67 |
| Heart Failure | 0.6 | 0.5 | 0.2 |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hyperglycemia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.6 | 1.2 | -1 |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.6 | 0.6 | 0 |
| Inflammatory Bowel Disease | 0.6 | 1.4 | -1.33 |
| Insomnia | 0.6 | 1.1 | -0.83 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 1.2 | 1.1 | 0.09 |
| ischemic stroke | 0.6 | 0.8 | -0.33 |
| Liver Cirrhosis | 1.1 | 1.1 | 0 |
| Long COVID | 0.6 | 0.9 | -0.5 |
| Low bone mineral density | 0.5 | -0.5 | |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | |
| ME/CFS with IBS | 0.3 | 0.3 | 0 |
| ME/CFS without IBS | 0.3 | 0.3 | 0 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 1.1 | 1.1 | 0 |
| Mood Disorders | 1.7 | 1.5 | 0.13 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 0.4 | 1.1 | -1.75 |
| Multiple system atrophy (MSA) | 0.1 | 0.1 | |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 0.8 | -0.8 | |
| Neuropathy (all types) | 0.3 | 0.5 | -0.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.1 | 0.8 | 0.38 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 1.1 | 1.5 | -0.36 |
| obsessive-compulsive disorder | 0.6 | 0.6 | 0 |
| Osteoarthritis | 0.6 | 0.6 | 0 |
| Osteoporosis | 0.8 | 0.6 | 0.33 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 1.1 | 1.4 | -0.27 |
| Polycystic ovary syndrome | 1.1 | 1.1 | 0 |
| primary biliary cholangitis | 0.3 | 0.3 | 0 |
| Primary sclerosing cholangitis | 0.7 | 0.7 | |
| Psoriasis | 0.3 | 0.8 | -1.67 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.1 | 0.8 | 0.38 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 0.6 | 0.8 | -0.33 |
| Sjögren syndrome | 0.3 | 0.3 | 0 |
| Sleep Apnea | 0.8 | -0.8 | |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 0.8 | 0.8 | 0 |
| Systemic Lupus Erythematosus | 0.6 | 0.5 | 0.2 |
| Tic Disorder | 0.3 | 0.3 | |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 0.6 | 1.1 | -0.83 |
| Type 2 Diabetes | 1.1 | 1.2 | -0.09 |
| Ulcerative colitis | 0.6 | 0.9 | -0.5 |
| Unhealthy Ageing | 0.6 | 0.5 | 0.2 |
| Vitiligo | 0.6 | 0.6 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
